×
About 10,520 results

ALLMedicine™ Cholangiocarcinoma Center

Research & Reviews  3,871 results

Single-cell landscape of immunocytes in patients with extrahepatic cholangiocarcinoma.
https://doi.org/10.1186/s12967-022-03424-5 10.1016/S0140-6736(13)61903-0 10.1634/theoncologist.2015-0446 10.3390/ijms19102885 10.1001/jamaoncol.2020.0930 10.1016/j.jhep.2017.01.010 10.1371/journal.pgen.1004135 10.1016/j.humpath.2017.02.001 10.1016/j.cell.2017.04.014 10.1038/s41591-018-0045-3 10.1016/j.cell.2017.05.035 10.1016/j.cell.2019.10.003 10.1038/s41586-018-0694-x 10.1126/science.aad0501 10.1016/j.jhep.2020.05.039 10.1093/bioinformatics/bts635 10.1038/nbt.4096 10.1038/srep33892 10.1038/s41590-018-0276-y 10.1038/s41596-020-0292-x 10.1093/bioinformatics/btz292 10.1038/nmeth.4437 10.1016/j.cell.2017.05.035 10.4049/jimmunol.177.2.1070 10.1084/jem.20151289 10.1002/iid3.85 10.1126/science.aad0501 10.1016/j.immuni.2016.10.021 10.1016/j.cell.2017.11.006 10.1038/ncomms9306 10.1038/s41421-020-0157-z 10.1016/j.jhep.2019.03.014 10.3389/fimmu.2017.01097 10.3389/fimmu.2020.01071 10.1016/j.jim.2018.11.001 10.3389/fimmu.2018.00744 10.1038/s41467-019-10335-5 10.1093/jnen/64.6.523 10.1158/1078-0432.CCR-19-2095 10.1073/pnas.1621280114 10.1038/onc.2016.458 10.1016/j.immuni.2014.06.011 10.1016/j.canlet.2020.01.005 10.1111/bjh.16158 10.1038/s41421-020-00214-5 10.1146/annurev-immunol-032414-112049 10.1053/j.seminoncol.2010.09.013 10.1038/ni759 10.3390/ijms21207619 10.4049/jimmunol.1201018 10.1038/cr.2016.151 10.18632/oncotarget.5176 10.1158/0008-5472.CAN-11-2493 10.4049/jimmunol.0902813 10.1002/hep.31278
Journal of Translational Medicine; Xu L, Lu Y et. al.

May 14th, 2022 - The intricate landscape of immunocytes in the tumor microenvironment (TME) is fundamental to immunotherapy but notably under-researched in extrahepatic cholangiocarcinoma (ECCA). Single-cell RNA sequencing technology was conducted to make an in-de...

NOTCH-YAP1/TEAD-DNMT1 axis drives hepatocyte reprogramming into intrahepatic cholangioc...
https://doi.org/10.1053/j.gastro.2022.05.007
Gastroenterology Hu S, Molina L et. al.

May 14th, 2022 - Intrahepatic cholangiocarcinoma (ICC) is a devastating liver cancer with extremely high intra- and inter-tumoral molecular heterogeneity, partly due to its diverse cellular origins. We investigated clinical relevance and the molecular mechanisms u...

Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).
https://clinicaltrials.gov/ct2/show/NCT04566133

May 13th, 2022 - Background: Among the new cases of bile tract carcinoma (BTC) that are diagnosed every year in the United States, there are approximately 6,500 cases of gallbladder carcinoma, 3,000 cases of extrahepatic cholangiocarcinoma, and 3,000 cases of intr...

Hepatobiliary Cancers: Progress in Diagnosis, Pathogenesis, and Treatment.
https://doi.org/10.1177/15330338221097203
Technology in Cancer Research & Treatment; Pant K, Gradilone SA

May 13th, 2022 - Hepatobiliary cancers comprise a wide range of malignancies such as hepatocellular carcinoma and cholangiocarcinoma, and they are some of the most challenging to treat human neoplasms. Due to the rarity of the illnesses, the development of treatme...

see more →

Guidelines  9 results

External Beam Radiation Therapy for Primary Liver Cancers: An ASTRO Clinical Practice G...
https://doi.org/10.1016/j.prro.2021.09.004
Practical Radiation Oncology; Apisarnthanarax S, Barry A et. al.

Oct 25th, 2021 - This guideline provides evidence-based recommendations for the indications and technique-dose of external beam radiation therapy (EBRT) in hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (IHC). The American Society for Radiation...

Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2021.0022
Journal of the National Comprehensive Cancer Network : JN... Benson AB, D'Angelica MI et. al.

May 25th, 2021 - The NCCN Guidelines for Hepatobiliary Cancers focus on the screening, diagnosis, staging, treatment, and management of hepatocellular carcinoma (HCC), gallbladder cancer, and cancer of the bile ducts (intrahepatic and extrahepatic cholangiocarcino...

Clinical practice guidelines for the management of biliary tract cancers 2019: The 3rd ...
https://doi.org/10.1002/jhbp.870
Journal of Hepato-biliary-pancreatic Sciences; Nagino M, Hirano S et. al.

Dec 2nd, 2020 - The Japanese Society of Hepato-Biliary-Pancreatic Surgery launched the clinical practice guidelines for the management of biliary tract cancers (cholangiocarcinoma, gallbladder cancer, and ampullary cancer) in 2007, then published the 2nd version ...

AGA Clinical Practice Update on Surveillance for Hepatobiliary Cancers in Patients With...
https://doi.org/10.1016/j.cgh.2019.07.011
Clinical Gastroenterology and Hepatology : the Official C... Bowlus CL, Lim JK et. al.

Jul 16th, 2019 - The purpose of this clinical practice update is to define key principles in the surveillance of hepatobiliary cancers including cholangiocarcinoma, gallbladder adenocarcinoma, and hepatocellular carcinoma in patients with primary sclerosing cholan...

Clinical practice guidelines for IgG4-related sclerosing cholangitis.
https://doi.org/10.1002/jhbp.596
Journal of Hepato-biliary-pancreatic Sciences; Kamisawa T, Nakazawa T et. al.

Dec 24th, 2018 - IgG4-related sclerosing cholangitis (IgG4-SC) is a distinct type of cholangitis frequently associated with autoimmune pancreatitis and currently recognized as a biliary manifestation of IgG4-related disease. Although clinical diagnostic criteria o...

see more →

Drugs  3 results see all →

Clinicaltrials.gov  144 results

Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).
https://clinicaltrials.gov/ct2/show/NCT04566133

May 13th, 2022 - Background: Among the new cases of bile tract carcinoma (BTC) that are diagnosed every year in the United States, there are approximately 6,500 cases of gallbladder carcinoma, 3,000 cases of extrahepatic cholangiocarcinoma, and 3,000 cases of intr...

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
https://clinicaltrials.gov/ct2/show/NCT04521686

Apr 28th, 2022 - This is an open-label, multicenter Phase 1 study to evaluate safety, tolerability and preliminary efficacy of oral LY3410738 in patients with IDH1 R132-mutant advanced solid tumors, including but not limited to cholangiocarcinoma, chondrosarcoma, ...

Chemo Alone or in Combination With Radiation in Unresectable Cholangiocarcinoma
https://clinicaltrials.gov/ct2/show/NCT02773485

Apr 27th, 2022 - Currently the standard of care of unresectable non-metastatic cholangiocarcinoma is chemotherapy which has a median survival of 11.7 months (ABC-02 study). While this study included almost 60% of patients with cholangiocarcinomas (intrahepatic, ex...

Clinical Trial of Autologous Tcm Immunotherapy in ICC
https://clinicaltrials.gov/ct2/show/NCT03820310

Apr 26th, 2022 - Intrahepatic cholangiocarcinoma (ICC) accounts for 2%~3% of gastrointestinal tumors, and the incidence has been on the rise globally. The pathogenesis of ICC remains unclearly. Compared with palliative resection, the postoperative survival rate of...

Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma
https://clinicaltrials.gov/ct2/show/NCT04088188

Apr 25th, 2022 - PRIMARY OBJECTIVE: I. To evaluate the safety, tolerability, maximum tolerated dose (MTD) and/or recommended phase 2 dose, gemcitabine and cisplatin in combination with either ivosidenib or pemigatinib. SECONDARY OBJECTIVES: I. To evaluate median a...

see more →

News  174 results

European Approval Sought for Ivosidenib in IDH1-Mutated AML and Cholangiocarcinoma
https://www.onclive.com/view/european-approval-sought-for-ivosidenib-in-idh1-mutated-aml-and-cholangiocarcinoma

Apr 22nd, 2022 - A marketing authorization application (MAA) has been submitted to the European Medicines Agency (EMA) for 2 indications of ivosidenib (Tibsovo): in combination with azacitidine in the frontline treatment of patients with IDH1-mutated acute myeloid...

KIN-3248 Under Exploration in Advanced Solid Tumors Harboring FGFR2 and/or FGFR3 Alterations
https://www.onclive.com/view/kin-3248-under-exploration-in-advanced-solid-tumors-harboring-fgfr2-and-or-fgfr3-alterations

Apr 21st, 2022 - The safety, tolerability, and preliminary efficacy of the irreversible, small molecule pan-FGFR inhibitor KIN-3248 is under investigation in adult patients with advanced tumors harboring FGFR2 and/or FGFR3 gene alterations, as part of the phase 1 ...

Targeted Combo Notches Rare Success in Glioblastoma
https://www.onclive.com/view/targeted-combo-notches-rare-success-in-glioblastoma

Mar 30th, 2022 - For more than 20 years, investigators have tried numerous targeted therapy strategies against glioblastoma (GBM) that have fallen frustratingly short in establishing clinical benefit.1 That changed in November 2021 when an international team of in...

2021 Approvals Expand Access to Care for Patients Across Tumor Types
https://www.onclive.com/view/2021-approvals-expand-access-to-care-for-patients-across-tumor-types

Mar 10th, 2022 - Last year marked the 50th anniversary of the National Cancer Act of 1971, a landmark legislation that committed to funding biomedical research, establishing oncology training programs, and building a nationwide network of cancer treatment centers....

Dr. Graham on the Role of the Pathologist in Biomarker Testing in Breast and GI Cancers
https://www.onclive.com/view/dr-graham-on-the-role-of-the-pathologist-in-biomarker-testing-in-breast-and-gi-cancers

Feb 1st, 2022 - Rondell P. Graham, MBBS, consultant, Division of Anatomic Pathology, Department of Laboratory Medicine and Pathology, associate professor of laboratory medicine and pathology, Mayo Clinic, discusses the role of the pathologist in biomarker testing...

see more →

Patient Education  7 results see all →